# A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

> **NCT01492361** · PHASE3 · COMPLETED · sponsor: **Amarin Pharma Inc.** · enrollment: 8179 (actual)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** AMR101
- **DRUG:** Placebo
- **DRUG:** Statin therapy

## Key facts

- **NCT ID:** NCT01492361
- **Lead sponsor:** Amarin Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 8179 (ACTUAL)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01492361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01492361, "A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT01492361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*